Biotia

Biotia provides sequencing-based solutions primarily to hospitals and clinical researchers, focusing on improving patient outcomes by enabling rapid and precise identification of pathogens and antimicrobial resistance. The company's business model centers on its proprietary platform, BIOTIA-ID, which combines next-generation sequencing (NGS) with an AI-driven software called Chelsea™. This integrated approach allows for the analysis of clinical samples, such as urine, to detect a comprehensive range of microorganisms—including bacteria, fungi, and viruses—often missed by traditional culturing methods. Revenue is generated through its diagnostic testing services and software platform. The company operates a CLIA-certified laboratory in New York, allowing it to process clinical samples from most U.S. states.

The company's core offering, BIOTIA-ID, is a diagnostic assay that provides a detailed microbial profile, identifies drug resistance markers, and flags emerging pathogens from a single test, with a turnaround time of approximately 24-72 hours. This platform is particularly aimed at complex cases like recurrent urinary tract infections (UTIs) and infections in immunocompromised patients. In November 2024, the BIOTIA-ID Urine NGS Assay received regulatory approval from the New York State Department of Health, a significant milestone validating its technology. Beyond individual diagnostics, Biotia has developed GeoSeeq, a platform supported by The Rockefeller Foundation, to create a global early warning system for pandemics by enabling researchers worldwide to share and analyze genomic data. The company has secured $10.4 million in funding over two rounds, including an $8 million Series A in August 2022 led by OCA Ventures, to expand its technological capabilities and market reach.